J Glaucoma. 2023 Jul 20. doi: 10.1097/IJG.0000000000002271. Online ahead of print.
ABSTRACT
PRECIS: This retrospective study found a statistically significant reduction in mean intraocular pressure and number of medications after intracameral Bimatoprost SR injection in patients with glaucoma. A history of selective laser trabeculoplasty did not impact treatment outcomes.
PURPOSE: To determine outcomes of Bimatoprost sustained release (Bimatoprost SR) on intraocular pressure (IOP) and number of topical IOP lowering medications in patients with glaucoma. A secondary objective was to determine the outcomes of Bimatoprost SR in patients with a prior history of selective laser trabeculoplasty (SLT).
METHODS: Retrospective case series. One hundred and eighteen eyes from 84 patients that received Bimatoprost SR by 6 glaucoma specialists at Wills Eye Hospital from March 2020 to September 2021 were examined. The intervention was a single injection of intracameral Bimatoprost SR. Main outcome measures included IOP and number of medications.
RESULTS: The mean most recent follow-up time for all eyes was 27.8±18.6 weeks. Mean post-treatment IOP at most recent follow-up of 16.6±5.3 mmHg was significantly lower than mean under therapy pre-treatment IOP of 18.5±5.7 mmHg for all eyes (P<0.01). Mean post-treatment number of medications at most recent follow-up of 1.3±1.3 decreased compared to number of pre-treatment medications of 2.1±1.4 for all eyes (P<0.01). Analysis of multilevel models controlling for demographic variables demonstrated a statistically significant reduction in IOP and number of medications post-treatment (P<0.01). A prior history of SLT (n=54) had no impact on treatment for both IOP and number of medications (P>0.1 for both).
CONCLUSIONS: Intracameral Bimatoprost SR reduced IOP and decreased the number of medications. Prior history of SLT did not impact Bimatoprost SR treatment outcomes.
PMID:37523637 | DOI:10.1097/IJG.0000000000002271
